StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen Reiterates Buy Rating on Neogenomics (NEO): reimbursements 'could drive '26 revenue growth 3-4% higher'
March 16, 2026 9:39 AM
TD Cowen analyst Dan Brennan reiterated a Buy rating and $16.00 price target on Neogenomics (NASDAQ: NEO)The analyst commented, "This ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
